Phased Innovation Awards (PIA)
Innovation grants involve a high degree of risk, innovation, and novelty with some promise for improving vaccine development. Although there is no requirement for preliminary data, strong scientific rationale is advisable.
Awarded projects will first be tested in milestone-driven exploratory/feasibility "proof of concept" studies (R21 phase); and then, if eligible, will be reviewed for the expanded development (R33 phase) award without the need to submit an additional grant application. The phased R21/R33 mechanism offers the potentially successful investigator the opportunity to devote full attention to the research project without the burden of additional grant writing for continued support, and will permit promising research to continue with no lapse in funding.
PIA Contact Information
Jon Warren, Ph.D.
Telephone: 301-402-0633
Fax: 301-402-3684
Email: jwarren@niaid.nih.gov
Current Awardees:
Stephen Dewhurst
Overcoming Low HIV-1 Envelope Spike Immunogenicity by High Density Display
University of Rochester Medical Center
Eckhard Podack
Induction of Mucosal SIV Immunity in Non-Human Primates by Secreted Hsp-Gp96
University of Miami
Haynes Sheppard
Whole Inactivated HIV-1; Stabilization and Immunogenicity Display
Public Health Foundation Enterprises
David Curiel
Capsid-Incorporation of HIV Antigens as a Novel Adenovirus HIV Vaccine Approach
University of Alabama at Birmingham
Donald Forthal
Fcg Receptor Polymorphisms and Risk of HIV Infection
University of California at Irvine
Anna-Lise Williamson
BCG as an HIV Vaccine Vector
University of Cape Town